Clin2
NCT07540897Likely a fitRecruiting

Testing ALKS 2680 for narcolepsy type 1

Narcolepsy Type 1

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
150 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You have been diagnosed with narcolepsy type 1, confirmed by a sleep study or CSF hypocretin test
  • You do not have other sleep disorders or conditions affecting your sleep-wake cycle
  • You are not currently in another clinical trial and have not taken any experimental medications in the past 30 days
  • You do not have other serious medical conditions that could affect your safety in the study
  • If you are a woman, you are not pregnant, breastfeeding, or planning to become pregnant during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07455383Recruiting· Phase 3
Testing ALKS 2680 for adults with narcolepsy type 1

This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.

Cullman, Alabama
NCT06767683Recruiting· Phase 2/Phase 3
Long-term study of ALKS 2680 for narcolepsy and idiopathic hypersomnia

This study is for people with narcolepsy or idiopathic hypersomnia who have already taken part in an earlier ALKS 2680 study. It aims to see how well the medication works and how safe it is when taken for a longer time.

Cullman, Alabama
NCT05816382Recruiting· Phase 2/Phase 3
Testing TAK-861 for narcolepsy type 1 sleepiness

This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.

Birmingham, Alabama
NCT07633301Recruiting· Phase 2
TAK-360 Study for Adults With Narcolepsy Type 1

This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.

Redwood City, California
NCT07598708Recruiting· Phase 2/Phase 3
Cleminorexton for Narcolepsy: A New Treatment Study

This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.

Colorado Springs, Colorado
NCT07727239Recruiting
Brain stimulation trial for people with narcolepsy type 1

This trial tests a non-invasive brain stimulation method called temporal interference to target the hypothalamus. It aims to help reduce excessive daytime sleepiness in people with narcolepsy type 1.

Xi'an, Shaanxi

Hear when a new Narcolepsy Type 1 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.